Which way forward for treatment of severe ocular inflammation?
Lightman
Sue
S
McCluskey
Peter J
PJ
D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy / Q000191:economics; D000069285:Infliximab; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D014222:Triamcinolone Acetonide / Q000191:economics / Q000627:therapeutic use; D014605:Uveitis / Q000188:drug therapy* / Q000191:economics
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D000069285:Infliximab; D014222:Triamcinolone Acetonide